Back to top

Image: Bigstock

Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta

Read MoreHide Full Article

For Immediate Release

Chicago, IL – January 20, 2020 – Stocks in this week’s article are Zumiez Inc. (ZUMZ - Free Report) , Neurocrine Biosciences Inc. (NBIX - Free Report) and Covanta Holding Corp. (CVA - Free Report) .

Look Beyond Earnings Growth with These 3 Winning Stocks

Fourth-quarter 2019 earnings season has just kicked off with the 31 S&P 500 members reporting results, per Earnings Trends issued on Jan 15, 2020. Total earnings (or aggregate net income) are down 5.7% year over year on 3.5% higher revenues, with 77.4% surpassing EPS estimates and 74.2% beating on revenues.

While earnings weakness appears to be worrisome so far, impressive beat ratios are giving investors every reason to bet big on an equity market rally. This is because higher earnings (irrespective of the magnitude) are no more that important for solid moves in stock prices. It is the “beat” that matters the most.

Why Should You Prioritize Earnings Beat?

A positive earnings surprise or earnings beat is typically the case when actual or reported earnings come in above the consensus estimate. Historically, if a company’s earnings manage to beat market expectations, its stock surges post release.

This is because investors always try to take positions ahead of time and look for stocks that are likely to come up with a stellar performance. Now, since Wall Street analysts project earnings of companies after much deliberation, their estimates act as investment leads.

After all, only earnings beat can give investors a clear picture of a company’s strength when an industry-wide earnings recession is felt. A 20% earnings rise (though apparently looks good) doesn’t tell you everything about the company’s performance. This might represent a decelerating earnings growth momentum over the years or quarters, raising questions over the company’s fundamentals.

Also, seasonal fluctuations come into play at times. If a company’s Q1 is seasonally weak and Q4 is strong, then it is likely to report a sequential earnings decline. In such cases, growth rates are misleading while judging the true health of a company.

How to Find the Hidden Gems?

Now, finding stocks that have the potential to beat on the bottom line may be investors’ dream but not an easy job. One way to do this is to look at the earnings surprise history of the company.

An impressive record in this regard generally acts as a catalyst for the stock. It indicates the company’s ability to surpass estimates. And investors generally believe that the company will apply the same secret sauce to execute yet another earning beat in its next release.

For the rest of this Screen of the Week article please visit Zacks.com at:https://www.zacks.com/stock/news/722278/look-beyond-earnings-growth-tap-the-beat-with-these-3-stocks

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine.  But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.

Follow us on Twitter:  http://twitter.com/zacksresearch

Join us on Facebook:  http://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Contact: Jim Giaquinto

Company: Zacks.com

Phone: 312-265-9268

Email: pr@zacks.com

Visit: www.Zacks.com

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.

 

 

 

                                                                                     


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Neurocrine Biosciences, Inc. (NBIX) - free report >>

Zumiez Inc. (ZUMZ) - free report >>

Covanta Holding Corporation (CVA) - free report >>